Status:
UNKNOWN
The Application Value of 18F-prostate-specific Membrane Antigen PET/CT in Prostate Cancer
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University
Conditions:
Prostatic Neoplasms
Eligibility:
MALE
40-100 years
Brief Summary
Prostate cancer (PCa) is the most common type of malignant tumor and the third leading cause of cancer-associated mortality among men worldwide. The biological behaviors of PCa at different degrees of...
Detailed Description
Prostate cancer (PCa) is the highest malignant male tumor and one of the leading causes of mortality among men worldwide. The biological behaviors of PCa malignancy are largely heterogeneous, directly...
Eligibility Criteria
Inclusion
- 1 age between 40 and 100 years old
- 2 PSA \>0.4 ng/mL for primary PCa with biopsy proven or RP diagnosis of prostate cancer
- 3 PSA \>0.2 ng/mL after RP, PSA ≥2 ng/mL above the nadir after EBRT) or persisting PSA after radical treatment with rising PSA values
- 4 complete clinical, pathological, imaging and biochemical information
Exclusion
- 1 lack of histological examinationproven diagnosis of PCa
- 2 18F-PSMA PET/CT being performed after pharmacotherapy since PSMA-targeted imaging can be disturbed by previous therapie
Key Trial Info
Start Date :
August 22 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2023
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04521894
Start Date
August 22 2021
End Date
August 31 2023
Last Update
June 9 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
First Affiliate Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China, 710061